Literature DB >> 1318376

Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances in rats through sigma and cholecystokinin receptors.

M Gue1, J L Junien, C Del Rio, L Bueno.   

Abstract

The effects of neuropeptide Y (NPY), sigma ligand (JO 1784) and sulfated cholecystokinin octapeptide (CCK8s) on emotional stress (ES) and corticotropin-releasing hormone (CRH)-induced colonic hypermotility were evaluated in rats equipped with chronically implanted electrodes on the colon and a small catheter into the lateral ventricle of the brain. A 139% (97-172%) increase in colonic spike burst frequency was observed in rats placed in a test cage in which they had previously received electric footshocks, an event assimilated to an ES. Intracerebroventricular injection of CRH (0.5 microgram/kg) mimicked the effects of ES by increasing colonic spike burst frequency by 89.0%. Given i.c.v., both JO 1784 (0.1 microgram/kg) and NPY (0.15 microgram/kg) blocked these stimulatory effects. Similarly, i.c.v. administration of CCK8s (0.1 microgram/kg) abolished both ES and CRH stimulated colonic motility, an effect reproduced by central injection of JMV 180, a cholecystokinin (CCK) derivative with high affinity for CCKA receptors, (1 microgram/kg), but not by JMV 170, a CCK derivative with low affinity for CCKA receptor at similar or higher dose. BMY 14802 (a sigma receptor antagonist) injected s.c. (1 mg/kg) abolished the antagonistic effects of JO 1784 and NPY on the ES-induced colonic hyperkinesia. Injected i.c.v., devazepide (L 364,718), a CCKA receptor antagonist, at 0.1 and 1 microgram/kg, abolished the effect of both JO 1784 and NPY; by contrast L365,260, a CCKB antagonist, required a dose of 10 micrograms/kg to block the antagonistic effect of NPY and JO 1784.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318376

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Electrophysiological evidence for the implication of cholecystokinin in the modulation of the N-methyl-D-aspartate response by sigma ligands in the rat CA3 dorsal hippocampus.

Authors:  B Gronier; G Debonnel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

Review 2.  Trauma and the gut: interactions between stressful experience and intestinal function.

Authors:  R Stam; L M Akkermans; V M Wiegant
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

Review 4.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Attenuation by a sigma1 (sigma1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats.

Authors:  Johann Meunier; Michèle Gué; Max Récasens; Tangui Maurice
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

6.  Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin-releasing factor-induced inhibition of gastric acid secretion in rats.

Authors:  M Gué; M Yoneda; H Mönnikes; J L Junien; Y Taché
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

7.  Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat.

Authors:  M Gué; C Gleïzes-Escala; C Del Rio-Lacheze; J L Junien; L Buéno
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

8.  The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxin.

Authors:  F P Monnet; G Debonnel; R Bergeron; B Gronier; C de Montigny
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.

Authors:  M Gué; J L Junien; J R Reeve; J Rivier; D Grandt; Y Taché
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.